UCD19 CAR T for adult ALL with MRD in remission
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to do daily activities at least fairly well (ECOG 0–2).
- Have confirmed B-cell ALL in first complete remission, with less than 5% blasts on blood/bone marrow testing.
- Have MRD positivity in remission (cancer still detectable at very low levels), with timing rules after standard chemotherapy.
- No prior CAR T treatment; no active or growing leukemia signs or mixed leukemia types (like mixed phenotype acute leukemia or Burkitt lymphoma).
- Be healthy enough for treatment: stable recovery from prior side effects (no worse than Grade 2), adequate blood counts, and organ tests within required limits (kidney, liver, oxygen/lung, and heart).
- Be able to safely donate cells for CAR T (apheresis): CD3 count above the required level and no uncontrolled infection or certain serious hepatitis/HIV history.
- If you can get pregnant or can father a child: agree to effective birth control starting now and for 12 months after the CAR T infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR T-cell therapy called KTE-X19 for people with B-cell ALL that is in remission but still has trace disease (MRD-positive). The goal is to see if this treatment can eliminate the remaining cancer cells and prevent relapse.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
Hear when a new Acute Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.